Abstract
Background: Despite commercially improved, standardized routine methods used in medical laboratories, precision laboratory medicine lacks harmonization of results to make the laboratory result useful for its intended purpose. Furthermore, in order to obtain reliable laboratory results and precise diagnoses, it is important and recommended that each laboratory confirms the analytical and clinical characteristics of the method used. The aim of this study was to evaluate the analytical and clinical performance of the IMMULITE®2000 TSI bridge immunoassay for the determination of autoreactive thyroid stimulating hormone receptor antibodies (ТSH-R-Ab).
Methods: A total of 86 patients with clinically present Graves' orbitopathy and 23 healthy volunteers as a control group were included in the study. The total TSH-R-Ab concentration was determined using an ECLIA (Elecsys Anti-TSHR Immunoassay Roche Diagnostics, GmbH, Mannheim, Germany) on the Cobas e411 analyzer (Roche, Diagnostics, GmbH). The TSH-R-Ab concentration was measured using a CLIA method (IMMULITE TSI 2000, Siemens Healthcare Diagnostics, UK). The inaccuracy of the method was investigated using two levels of commercial control samples (low and high analyte concentration).
Results: The results obtained meet the general minimum requirements for the analytical performance of laboratory methods (CV <5%). The overall laboratory inaccuracy was acceptable according to FDA guidelines (CV<20%). The results showed a statistically significant correlation between the analyzed methods (r=0.9041, p ˂ 0.0001), but with a relative bias of 24.5%. The best ratio of sensitivity and specificity determined by the ROC analysis (93.3 % and 100 % respectively) was obtained for a cut-off value of 0.1215 IU/L, which is significantly lower compared to the cut-off value specified by the manufacturer (0.55 IU/L).
Conclusion: The IMMULITE 2000 TSI bridge immunoassay for TSH-R-Ab quantification confirmed an adequate level of precision, which is essential for routine use. However, further studies are required to evaluate its analytical specificity.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.